Tradegate
29.06.26 | 16:47
0,035 Euro
+6,15 % +0,002
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,030 | 0,035 | 29.06. | |
| 0,030 | 0,035 | 29.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| HEMOSTEMIX Aktie jetzt für 0€ handeln | |||||
| Fr | Hemostemix Inc (2): Hemostemix closes $360,000 first tranche of placement | 1 | Stockwatch | ||
| Fr | Hemostemix Inc.: Hemostemix Closes $360,000 First Tranche of Private Placement | 308 | Newsfile | Calgary, Alberta--(Newsfile Corp. - June 26, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the first tranche... ► Artikel lesen | |
| 17.06. | Hemostemix Inc.: Hemostemix' $1,000,000 Private Placement and Update | 488 | Newsfile | Calgary, Alberta--(Newsfile Corp. - June 17, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $1,000,000 of financing in tranches... ► Artikel lesen | |
| 09.03. | Hemostemix Inc.: Hemostemix Leadership Attending Abundance360 Summit | 485 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas Smeenk CEO and Peter Lacey, Chairman are attending the 2026... ► Artikel lesen | |
| 04.02. | Hemostemix Inc (2): Hemostemix appoints Hsiang as business consultant | 3 | Stockwatch | ||
| 03.02. | Hemostemix Inc.: Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships | 275 | Newsfile | Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral... ► Artikel lesen | |
| 16.01. | Hemostemix Inc.: Hemostemix Receives FDA Support for Its Basket Protocol Approach | 577 | Newsfile | Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral... ► Artikel lesen | |
| 01.01. | Hemostemix Inc (2): Hemostemix closes $480,000 financing | 4 | Stockwatch | ||
| 31.12.25 | Hemostemix Inc.: Hemostemix Closes $480,000 Private Placement at $0.12 per Share | 408 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"), an autologous stem cell company treating those who... ► Artikel lesen | |
| 23.12.25 | Hemostemix Inc.: Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01 | 541 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous stem cell company treating those who... ► Artikel lesen | |
| 11.12.25 | Hemostemix Inc.: Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv) | 395 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 11.12.25 | Hemostemix Inc.: Hemostemix Grants Stock Options | 327 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock... ► Artikel lesen | |
| 10.12.25 | Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000 | 490 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy... ► Artikel lesen | |
| 04.12.25 | Hemostemix Inc.: Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations | 442 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic... ► Artikel lesen | |
| 03.12.25 | Hemostemix Inc.: Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14 | 519 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its participation as a premier... ► Artikel lesen | |
| 02.12.25 | Hemostemix Inc.: Hemostemix to Attend DFCon San Antonio and Closed its Private Placement | 449 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation... ► Artikel lesen | |
| 26.11.25 | Hemostemix Inc.: Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two | 531 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), is pleased to announce a binding Letter of Intent for the acquisition of the first two... ► Artikel lesen | |
| 20.11.25 | Hemostemix Inc.: Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia | 265 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 18.11.25 | Hemostemix Inc.: Hemostemix Closes CDN$280,594 Private Placement | 516 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy... ► Artikel lesen | |
| 18.11.25 | Hemostemix Inc.: Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida | 462 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a leader in regenerative medicine, will attend the Innovations in Wound Care Conference... ► Artikel lesen |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,968 | +2,69 % | Blockbuster, Gold und Insiderverkäufe - Bayer AG, Evotec, North Arrow Minerals | Der erneute israelische Angriff im Libanon blockiert die eh schon unsicheren US-Iran-Gespräche massiv. Da Teheran die Hisbollah im Libanon unterstützt und den Frieden mit den USA an einen Frieden zwischen... ► Artikel lesen | |
| MEDIGENE | 0,017 | -18,10 % | Medigene AG: Widerruf der Zulassung zum regulierten Markt | Beschluss
Medigene AG, Planegg
Widerruf der Zulassung zum regulierten Markt
Auf Antrag der Gesellschaft wird die Zulassung der auf den Namen lautenden Stammaktien (ISIN: DE000A40ESG2) zum regulierten... ► Artikel lesen | |
| QIAGEN | 34,570 | +0,14 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 38 auf 40 Euro angehoben und die Einstufung auf "Kaufen" belassen. Das Thema Künstliche Intelligenz (KI) sei für den Life-Science-Zuliefersektor... ► Artikel lesen | |
| PAION | 0,071 | 0,00 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,271 | +0,22 % | VALNEVA SE: Valneva Announces Successful Outcome of its Annual General Meeting | Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that... ► Artikel lesen | |
| EPIGENOMICS | 0,870 | 0,00 % | PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung | DJ PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Hauptversammlung gemäß -- 121 Abs. 4a AktG
Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Heidelberg... ► Artikel lesen | |
| NOVAVAX | 8,160 | +4,48 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| STRYKER | 288,70 | -1,13 % | Stryker Corporation (SYK) launches TPX HD Power Tool | ||
| CRISPR THERAPEUTICS | 49,230 | +2,18 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected... ► Artikel lesen | |
| CO.DON | 0,015 | -35,56 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| OCUGEN | 1,468 | +12,58 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 132,66 | +0,08 % | Apogee Therapeutics: Hier dürfte zum US-Handelsstart heute die Post abgehen! | AbbVie steht laut einem Bericht kurz vor der Übernahme von Apogee Therapeutics für rund 10,9 Milliarden US-Dollar in bar. Der mögliche Aufschlag liegt bei etwa 60 Prozent. Weil die US-Börsen am Freitag... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 349,93 | 0,00 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 32,550 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| VERA THERAPEUTICS | 43,130 | 0,00 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen |
HEMOSTEMIX INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,035 Euro und damit +6,15 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMOSTEMIX INC finden Sie auf Wallstreet Online.